ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1592

ACT for Lupus: Pilot Study of a Novel Acceptance and Commitment Therapy (ACT) Online Program to Support Patients with Lupus During the COVID-19 Pandemic

Tessa Englund1, Saira Sheikh2, Becki Cleveland1, Emily McCormick1, Crystal Schiller3 and Teresa Dickson1, 1Thurston Arthritis Research Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, 2University of North Carolina Thurston Arthritis Research Center, and Department of Medicine, Division of Rheumatology, Allergy and Immunology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, 3University of North Carolina at Chapel Hill, Chapel Hill, NC

Meeting: ACR Convergence 2021

Keywords: COVID-19, education, patient, mental health, Patient reported outcomes, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 9, 2021

Title: Patient Outcomes, Preferences, & Attitudes Poster IV: COVID-19 (1589–1613)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic disease associated with significant symptom burden, including fatigue, anxiety, depression, pain, and negative impacts on health-related quality of life (HRQoL). The COVID-19 pandemic has resulted in additional stressors impacting the mental health and well-being of patients with SLE. Acceptance and Commitment Therapy (ACT) is a promising treatment approach that has shown efficacy in addressing many of the symptoms associated with SLE, such as such as depression, anxiety, and chronic pain. The goal of this pilot study was to develop and assess the feasibility and preliminary efficacy of ACT for Lupus, a novel online ACT-based virtual skills training program tailored for patients with lupus.

Methods: Participants with a diagnosis of SLE were primarily recruited through an academic healthcare system in North Carolina, as well as nationally in partnership with a large lupus advocacy organization. A total of 72 participants completed the baseline survey and were invited to attend two weekly one-hour webinar sessions in December 2020, which were delivered through a web-based platform. Educational content was tailored for patients with lupus and delivered by an experienced clinical psychologist who specializes in ACT. Topics and practice exercises encompassed ACT-principles of mindfulness, distress tolerance, self-care and advocacy, goal setting, and action planning. Patient-reported outcomes (PROs) including anxiety (General Anxiety Disorder-7; GAD-7), depression (Patient Health Questionnaire; PHQ-9), and disease-specific HRQoL (LupusQoL) were assessed at baseline and post-intervention. Additional questions in the follow-up survey assessed participant satisfaction with the program and suggestions/opportunities for refinement. Means and effect sizes (ES) with 95% confidence intervals (CIs) were computed for pre- and post- changes in PROs, adjusted for age, sex and baseline measurements (Table 2).

Results: Data was analyzed for a total of 23 individuals who participated in the program and submitted the end of study assessment survey. Most participants were women (86%), aged > 28 years, and recruited through the North Carolina system (82.6%) (Table 1). In pre- post- analyses of the ACT for Lupus pilot data, we found modest improvements in LupusQoL fatigue scores (ES=0.25) and reduced symptoms of anxiety as indicated by GAD-7 scores (ES= -0.26). Feedback from participants highlighted unmet needs for mindfulness-based programs, tailored to the unique experiences of patients with lupus. Participant feedback included suggestions to inform growth and expansion of the program and added flexibility for participants to access the program at their own pace in a self-directed format.

Conclusion: Preliminary results suggest that an adapted ACT-based virtual skills training program has potential to improve psychological and QoL outcomes among patients with lupus, especially in the face of additional stressors.

Table 1: Participant characteristics (n=23)

Table 2: Means (SD) and effect sizes for changes in outcomes from baseline to end of study (n=23)


Disclosures: T. Englund, None; S. Sheikh, Pfizer, 5, GlaxoSmithKline, 2, 5; B. Cleveland, None; E. McCormick, None; C. Schiller, None; T. Dickson, None.

To cite this abstract in AMA style:

Englund T, Sheikh S, Cleveland B, McCormick E, Schiller C, Dickson T. ACT for Lupus: Pilot Study of a Novel Acceptance and Commitment Therapy (ACT) Online Program to Support Patients with Lupus During the COVID-19 Pandemic [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/act-for-lupus-pilot-study-of-a-novel-acceptance-and-commitment-therapy-act-online-program-to-support-patients-with-lupus-during-the-covid-19-pandemic/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/act-for-lupus-pilot-study-of-a-novel-acceptance-and-commitment-therapy-act-online-program-to-support-patients-with-lupus-during-the-covid-19-pandemic/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology